LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Lexeo Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$2.76+0.12 (+4.55%)

Close on Oct 19, 2026

Market cap: $236.33M
P/E (TTM): –
Dividend yield: –

Lexeo Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31
Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.53	–	–
Research & Development	19	16	16	16	15	17	18	23	17	16	8.21	17	11	16	11	15	–	–
General & Administrative	8.99	6.63	6.91	5.95	16	17	9.02	8.12	6.99	7.55	6.76	3.03	2.74	2.85	3.81	2.65	–	–
Operating Expenses	28	22	23	22	31	34	27	32	24	23	15	20	14	19	15	18	–	–
Operating Income	-28	-22	-23	-22	-31	-34	-27	-32	-24	-23	-15	-20	-14	-19	-15	-17	–	–
Interest Expense	0.01	0.02	0.02	0.02	0.03	0.03	0.03	0.04	0.04	0.04	0.05	0.05	0.05	0.05	0.05	0.03	–	–
Interest & Investment Income	2.19	2.11	2.21	1.46	1.27	1.19	1.47	2.09	2.35	1.65	1.10	0.49	0.59	0.69	0.68	0.46	–	–
Other Non-Operating Income	2.15	2.14	2.20	1.37	4.59	1.15	1.46	2.05	2.31	1.61	0.79	0.17	0.53	0.63	0.62	0.43	–	–
Pretax Income	-26	-20	-21	-20	-26	-33	-26	-29	-21	-22	-14	-20	-13	-19	-15	-17	–	–
Net Income incl. Noncontrolling Interests	-26	-20	-21	-20	-26	-33	-26	-29	-21	-22	-14	-20	-13	-19	-15	–	–	–
Net Income	-26	-20	-21	-20	-26	-33	-26	-29	-21	-22	-14	-20	-13	-19	-15	-17	-15	-13
EPS (Basic)(per share)	-0.30	-0.25	-0.27	-0.33	-0.60	-0.99	-0.78	-0.89	-0.64	-0.77	–	-12.36	-8.30	-11.58	-8.86	-10.38	–	–
EPS (Diluted)(per share)	-0.30	-0.25	-0.27	-0.33	-0.60	-0.99	-0.78	-0.89	-0.64	-0.77	–	-12.36	-8.30	-11.58	-8.86	-10.38	–	–
Shares Outstanding (Basic, Weighted)(shares)	86	81	77	61	44	33	33	33	33	28	–	1.63	1.62	1.61	1.64	1.64	–	–
Shares Outstanding (Diluted, Weighted)(shares)	86	81	77	61	44	33	33	33	33	28	–	1.63	1.62	1.61	1.64	1.64	–	–
EBITDA	-28	-22	-23	-22	-31	-34	-27	-31	-23	-23	-15	-20	-14	-19	-15	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -55.0%

Financial strength

Current ratio: 13.89
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 591.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.01
Dividend yield: –